| Kristen Marie Zeller-hack, MD | |
|
3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 | |
| (952) 993-1000 | |
| Not Available |
| Full Name | Kristen Marie Zeller-hack |
|---|---|
| Gender | Female |
| Speciality | Interventional Pain Management |
| Experience | 30 Years |
| Location | 3800 Park Nicollet Blvd, St Louis Park, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316982382 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 46159 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.
More than nine out of ten clinicians believe that reducing readmissions is an important topic, but few have the resources at hand to tackle it, according to a new study from QuantiaMD®, the leading mobile and online physician community, and the Society of Hospital Medicine (SHM).
Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.
BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.
Massachusetts General Hospital (MGH) researchers are investigating a new way to block reproduction of the hepatitis C virus (HCV) - targeting not the virus itself but the human genes the virus exploits in its life cycle.
› Verified 8 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.
More than nine out of ten clinicians believe that reducing readmissions is an important topic, but few have the resources at hand to tackle it, according to a new study from QuantiaMD®, the leading mobile and online physician community, and the Society of Hospital Medicine (SHM).
Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.
BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.
Massachusetts General Hospital (MGH) researchers are investigating a new way to block reproduction of the hepatitis C virus (HCV) - targeting not the virus itself but the human genes the virus exploits in its life cycle.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Marie Zeller-hack, MD 8170 33rd Ave S, Mail Stop 21110q, Minneapolis, MN 55440-1309 Ph: (952) 883-6212 | Kristen Marie Zeller-hack, MD 3800 Park Nicollet Blvd, St Louis Park, MN 55416-2527 Ph: (952) 993-1000 |
News Archive
California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.
More than nine out of ten clinicians believe that reducing readmissions is an important topic, but few have the resources at hand to tackle it, according to a new study from QuantiaMD®, the leading mobile and online physician community, and the Society of Hospital Medicine (SHM).
Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.
BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.
Massachusetts General Hospital (MGH) researchers are investigating a new way to block reproduction of the hepatitis C virus (HCV) - targeting not the virus itself but the human genes the virus exploits in its life cycle.
› Verified 8 days ago
Edward V Violante, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
John P Newcome, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
Thomas E Lyons, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
Michael J Lyons, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
David J Yasmineh, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
Dr. John D. Zurn, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-920-0845 | |
Debra Yvonne Hamilton, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2300 Parklands Rd, St Louis Park, MN 55416 Phone: 952-920-2221 Fax: 952-920-2221 |